Long intergenic non-protein coding RNA 1252 (LINC01252)

Long intergenic non-protein coding RNA 1252 (LINC01252) is a human gene encoding a long intergenic non-coding RNA (lincRNA), a subclass of long non-coding RNAs defined as autonomously transcribed RNA transcripts longer than 200 nucleotides that do not overlap protein-coding genes[1][3][7]. LincRNAs are often highly tissue-specific and can modulate gene expression through mechanisms such as chromatin remodeling, interaction with transcription factors, scaffolding ribonucleoprotein complexes, and regulating RNA stability[3][4][5][7]. While LINC01252 itself is not established as a therapeutic target and has not been directly linked to specific drug interactions or mechanisms of action, the broader lincRNA class is increasingly recognized for regulatory roles in health and disease, especially in cancer biology[3][4][5][7]. No specific biological or clinical associations are documented for LINC01252[1]; it shares the general molecular features and regulatory functions attributed to the lincRNA family. Key notes: - LINC01252 is not a canonical drug target like receptors, enzymes, or transporters; it is a non-coding RNA with putative regulatory roles[1][3][7]. - There is no evidence of approved drugs, biomarkers, or known safety/toxicity concerns specifically for LINC01252. - Most current lincRNA research highlights the gene regulation and disease potential of the family rather than individual members unless specifically characterized[3][4][5].

Other names

LINC01252